CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes
Hansa Biopharma

Virtual Investor Event

Autoimmune Deep Dive
Guillain-Barré Syndrome 

Join Hansa Biopharma for an investor event featuring KOLs David R. Cornblath, MD (Johns Hopkins University), and Simon Rinaldi, MRCP(Neuro), PhD (University of Oxford), who will discuss the unmet need and current treatment landscape for Guillain-Barré syndrome (GBS), an acute, rare, paralyzing inflammatory disease of the peripheral nervous system.

16 June 2025, 14:00 CEST / 8:00 AM ET

Register and attend

General meeting

2025

25 Jun 2025
Annual General Meeting 2025

Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, Sweden, will hold its Annual General Meeting on Wednesday June 25, 2025 at 14:30 CEST, Elite Hotel Ideon, Scheelevägen 27, SE-223 63 Lund. Registration starts at 14:00 CEST. 

Information about the Annual General Meeting and the forms for its implementation will be provided in the notice convening the Annual General Meeting. 

Shareholders are entitled to have a matter dealt with at the Annual General Meeting provided that a request therefor has reached the Board of Directors no later than on 15 April 2025. The request shall be addressed to the Board of Directors but be sent to:

Hansa Biopharma AB 
Attn: General Counsel
Box 785
SE-220 07 Lund, Sweden